Genome-wide Association Study (GWAS) and Epigenome-wide Association Study (EWAS) in Patients With Erdheim-Chester Disease

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Genetic
Study Type: Observational
SUMMARY

Erdheim-Chester Disease (ECD) is a rare form of histiocytosis characterized by the proliferation of blood cells, known as histiocytes, which infiltrate various organs and tissues, often causing irreversible damage. The causes of the condition are still unknown, and although some mutations in genes involved in cell proliferation have been identified, other factors may be involved. Susceptibility to developing rare diseases like ECD is typically associated with genetic factors, including DNA polymorphisms and epigenetic modifications. This study aims to analyze the entire genome of a large cohort of patients with ECD and healthy controls to determine whether there are polymorphisms and epigenetic variants associated with susceptibility to developing the disease. The study could thus clarify the genetic predisposition to ECD development, provide insights into disease pathogenic mechanisms, and identify proteins or cellular mechanisms potentially targeted by specific treatments.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 99
Healthy Volunteers: f
View:

• \- ECD with histological confirmation of disease

Locations
Other Locations
France
Hopital Pitié Salpetrière
RECRUITING
Paris
Italy
Meyer Children's Hospital IRCCS
RECRUITING
Florence
IRCCS Ospedale San Raffaele
RECRUITING
Milan
AOU Parma
RECRUITING
Parma
Spain
Genetics Lab, CSIC
RECRUITING
Granada
Contact Information
Primary
Augusto Vaglio
augusto.vaglio@meyer.it
3200026532
Time Frame
Start Date: 2019-07-17
Estimated Completion Date: 2024-10-01
Participants
Target number of participants: 300
Treatments
Presence of polymorphisms
Statistical analysis of GWAS data, Genome-wide methylation pattern analysis, Integration of GWAS data and methylation data (meQTL analysis), Pathway enrichment analysis
Sponsors
Leads: Augusto Vaglio

This content was sourced from clinicaltrials.gov

Similar Clinical Trials